Servier Pharmaceuticals/LinkedIn
Aug 7, 2025, 12:11
Marking One Year of Progress in IDH-Mutant Glioma Treatment – Servier Pharmaceuticals
Servier Pharmaceuticals shared a post on LinkedIn:
“One year ago, Servier brought the first and only FDA–approved targeted therapy for Grade 2 IDH-mutant glioma to patients in the U.S., marking the first significant treatment breakthrough for this relentless condition in over two decades.
Today, our commitment remains stronger than ever as we continue to drive progress forward for patients and families affected by glioma and other IDH-mutated cancers. Learn more about our ongoing efforts here.”
More posts featuring Servier Pharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 7, 2025, 14:35
Aug 7, 2025, 13:56
Aug 7, 2025, 13:43
Aug 7, 2025, 12:39
Aug 7, 2025, 12:37